Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma

被引：20

作者：

van de Donk, Niels W. C. J. ^{[1
]}

Casneuf, Tineke ^{[2
]}

Di Cara, Alessandro ^{[3
]}

Parren, Paul W. ^{[4
,5
,6
]}

Zweegman, Sonja ^{[1
]}

van Kessel, Berris ^{[1
]}

Lokhorst, Henk M. ^{[1
]}

Usmani, Saad Z. ^{[7
]}

Lonial, Sagar ^{[8
]}

Richardson, Paul G. ^{[9
]}

Chiu, Christopher ^{[10
]}

Mutis, Tuna ^{[1
]}

Nijhof, Inger S. ^{[1
]}

Sasser, A. Kate ^{[10
]}

机构：

[1] Vrije Univ Amsterdam Med Ctr, Dept Haematol, Amsterdam, Netherlands

[2] Janssen Res & Dev, Beerse, Belgium

[3] Quartz Bio, Geneva, Switzerland

[4] Genmab, Utrecht, Netherlands

[5] Univ Southern Denmark, Dept Canc & Inflammat Res, Inst Mol Med, Odense, Denmark

[6] Leiden Univ, Med Ctr, Dept Immunohaematol & Blood Transfus, Leiden, Netherlands

[7] Carolinas Healthcare Syst, Levine Canc Inst, Charlotte, NC USA

[8] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA

[9] Harvard Med Sch, Jerome Lipper Myeloma Ctr, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA USA

[10] Janssen Res & Dev, Spring House, PA USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2019年 / 184卷 / 03期

关键词：

multiple myeloma; daratumumab; Fc gamma receptors; immunotherapy; polymorphisms; NATURAL-KILLER-CELLS; TARGETING CD38; MONOTHERAPY; ANTIBODIES;

D O I：

10.1111/bjh.15122

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：475 / 479

页数：5

共 50 条

[41] Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma [J].

Zahra Goudarzi ;

Rahil Sadat Shahtaheri ;

Zhila Najafpour ;

Haleh Hamedifar ;

Hamidreza Ebrahimi .

Cost Effectiveness and Resource Allocation, 22

[42] Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma [J].

Casneuf, Tineke ;

Xu, Xu Steven ;

Adams, Homer C., III ;

Axel, Amy E. ;

Chiu, Christopher ;

Khan, Imran ;

Ahmadi, Tahamtan ;

Yan, Xiaoyu ;

Lonial, Sagar ;

Plesner, Torben ;

Lokhorst, Henk M. ;

van de Donk, Niels W. C. J. ;

Clemens, Pamela L. ;

Sasser, A. Kate .

BLOOD ADVANCES, 2017, 1 (23) :2105-2114

[43] Practical considerations and role of Daratumumab retreatment for relapsed refractory Multiple Myeloma [J].

Kim, E. Bridget ;

Harrington, Cynthia ;

Yee, Andrew ;

O'Donnell, Elizabeth ;

Branagan, Andrew ;

Burke, Jill ;

Raje, Noopur .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10) :E263-E263

[44] Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma [J].

Chari, Ajai ;

Lonial, Sagar ;

Mark, Tomer M. ;

Krishnan, Amrita Y. ;

Stockerl-Goldstein, Keith E. ;

Usmani, Saad Z. ;

Londhe, Anil ;

Etheredge, Delores ;

Fleming, Sarah ;

Liu, Baolian ;

Ukropec, Jon ;

Lin, Thomas S. ;

Jagannath, Sundar ;

Nooka, Ajay K. .

CANCER, 2018, 124 (22) :4342-4349

[45] Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/ refractory multiple myeloma [J].

Cho, Hee Jeong ;

Jo, Jae-Cheol ;

Lee, Yoo Jin ;

Lee, Myung Won ;

Kim, Do Young ;

Shin, Ho Jin ;

Im, Sung Nam ;

Lee, Ji Hyun ;

Bae, Sung Hwa ;

Do, Young Rok ;

Lee, Won Sik ;

Kim, Min Kyung ;

Jung, Jina ;

Lee, Jung Min ;

Kim, Ju-Hyung ;

Baek, Dong Won ;

Sohn, Sang-Kyun ;

Moon, Joon Ho .

KOREAN JOURNAL OF INTERNAL MEDICINE, 2023, 38 (02) :238-+

[46] NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma [J].

Verkleij, Christie P. M. ;

Frerichs, Kristine A. ;

Broekmans, Marloes E. C. ;

Duetz, Carolien ;

O'Neill, Chloe A. ;

Bruins, Wassilis S. C. ;

Homan-Weert, Paola M. ;

Minnema, Monique C. ;

Levin, Mark-David ;

Broijl, Annemiek ;

Bos, Gerard M. J. ;

Kersten, Marie Jose ;

Klein, Saskia K. ;

Shikhagaie, Medya M. ;

Casneuf, Tineke ;

Abraham, Yann ;

Smets, Tina ;

Vanhoof, Greet ;

Cortes-Selva, Diana ;

van Steenbergen, Laure ;

Ramos, Elena ;

Verona, Raluca I. ;

Krevvata, Maria ;

Sonneveld, Pieter ;

Zweegman, Sonja ;

Mutis, Tuna ;

van de Donk, Niels W. C. J. .

HEMASPHERE, 2023, 7 (05) :E881

[47] Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments [J].

Offidani, Massimo ;

Corvatta, Laura ;

More, Sonia ;

Nappi, Davide ;

Martinelli, Giovanni ;

Olivieri, Attilio ;

Cerchione, Claudio .

FRONTIERS IN ONCOLOGY, 2021, 10

[48] Daratumumab therapy for relapsed or refractory multiple myeloma: a single-center retrospective study [J].

Kazutaka Sunami ;

Hiroyuki Murakami ;

Hisashi Tagashira ;

Hiroko Ueda ;

Takashi Moriyama ;

Tatsunori Ishikawa ;

Takanori Yoshioka ;

Masanori Makita .

International Journal of Clinical Oncology, 2020, 25 :2151-2157

[49] Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A "real world" experience [J].

Fucci, Ludovica ;

Gensini, Lorenzo ;

Coppetelli, Ugo ;

La Barbera, Elettra Ortu ;

Gentile, Martina ;

Fiori, Luciano ;

Perrone, Salvatore ;

Cimino, Giuseppe .

LEUKEMIA RESEARCH REPORTS, 2022, 17

[50] Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma [J].

Sanchez, Larysa ;

Richter, Joshua ;

Cho, Hearn Jay ;

Jagannath, Sundar ;

Madduri, Deepu ;

Parekh, Samir ;

Richard, Shambavi ;

Tam, Lowena ;

Verina, Daniel ;

Chari, Ajai .

THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12

← 1 2 3 4 5 →